Innovative therapeutic strategies for liver fibrosis target redox enzymes (such as NOX isoforms) or redox-dependent nuclear factors (such as nuclear factor erythroid 2-related factor 2, NRF2, and peroxisome proliferator-activated receptor-γ, PPAR-γ). This evidence concerns the gene NFE2L2 and Hepatic fibrosis.